U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast) tablets as first new treatment option for adults with IPF in over a decade
On Oct. 9, 2025, Boehringer Ingelheim’s JASCAYD® (nerandomilast) tablets has been approved by the U.S. Food and Drug…
idiopathic pulmonary fibrosis